Delving into the Latest Updates on Merck Sharp & Dohme Research Ltd. with Synapse

概览

关联

3

项与 Merck Sharp & Dohme Research Ltd. 相关的临床试验

EUCTR2006-005956-34-GB

/ Not yet recruiting临床2期

A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0822 in Patients with Osteoarthritis - Safety and Efficacy of MK-0822 in Patients with Osteoarthritis

开始日期2007-03-14

申办/合作机构

Merck Sharp & Dohme Research Ltd.

EUCTR2006-003924-13-GB

/ Not yet recruiting临床2期

A Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 2-Period Crossover Study to Assess the Efficacy and Safety of MK-0952 in Patients With Alzheimer’s Disease - MK-952 Proof of Concept Study

开始日期2006-11-14

申办/合作机构

Merck Sharp & Dohme Research Ltd.

EUCTR2005-002454-21-GB

/ Not yet recruiting临床2/3期

A 2-Year Study (1-Year Weight Loss Followed by 1-Year Prevention of Weight Regain) to Assess the Safety, Tolerability and Efficacy of Taranabant (MK-0364) in Obese Patients followed by a 1 year extension. - MK-0364: 1-Yr Weight Loss Followed by 1-Yr Prevention of Weight Regain

开始日期2005-07-29

申办/合作机构

Merck Sharp & Dohme Research Ltd.

100 项与 Merck Sharp & Dohme Research Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Merck Sharp & Dohme Research Ltd. 相关的专利（医药）

登录后查看更多信息

1

项与 Merck Sharp & Dohme Research Ltd. 相关的文献（医药）

1993-01-01·British Journal of Pharmacology

The non‐peptide neurokinin₁ receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats

Article

作者: Williamson, David J. ; Hargreaves, Richard J. ; Shepheard, Sara L. ; Hill, Raymond G.

A non‐peptide neurokinin1 (NK1) receptor antagonist, RP 67580, that is selective for the rodent subtype of the NK1 receptor, dose‐dependently reduced plasma extravasation in the dura mater produced by electrical stimulation of the trigeminal ganglion in rats, with an ID50 of 0.6 μg kg−1. Its enantiomer RP 68651 was some 400 fold less active. The results indicate that neurogenic plasma extravasation within the dura mater is NK1 receptor‐mediated and suggest that NK1 receptor antagonists may have a role as antimigraine agents.

100 项与 Merck Sharp & Dohme Research Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Merck Sharp & Dohme Research Ltd. 相关的转化医学

登录后查看更多信息